Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
  • USA - English


News provided by

RnR Market Research

Apr 21, 2015, 11:30 ET

Share this article

Share toX

Share this article

Share toX

Dermatitis Therapeutic Pipeline Review H1 2015
Dermatitis Therapeutic Pipeline Review H1 2015

Dallas, Texas (PRWEB) April 21, 2015 -- The report “Dermatitis – Pipeline Review, H1 2015” provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-pipeline-review-h1-2015-market-report.html .

The report also reviews key players involved in the therapeutic development for Dermatitis and special features on late-stage and discontinued projects. Companies discussed in this Dermatitis – Pipeline Review, H1 2015 report include AlbireoPharma, Amorepacific Corporation, Anacor Pharmaceuticals, Inc., AnaMar AB, AnaptysBio, Inc., AnGes MG, Inc., Aquinox Pharmaceuticals Inc., arGEN-X BV, Biomar Microbial Technologies, Blueberry Therapeutics Ltd, Brickell Biotech, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Celsus Therapeutics Plc, ChemoCentryx, Inc., China Biologic Products, Inc., ChironWells GmbH, Chugai Pharmaceutical Co., Ltd., Circassia Pharmaceuticals plc, Convoy Therapeutics, Inc., Creabilis SA, Daiichi Sankyo Company, Limited, Dermira Inc., Eisai Co., Ltd., EpiPharm AG, F. Hoffmann-La Roche Ltd., FAES Farma SA, Foamix Pharmaceuticals Ltd., Fountain Biopharma Inc., GlaxoSmithKline plc, GlycaNova Norway AS, Grupo Ferrer Internacional, S.A., Han Wha Pharma Co., Ltd., HanAll Biopharma Co., Ltd., Herantis Pharma plc., IMMD Inc., Immune Response BioPharma, Inc., Inflamalps SA, Janssen Research & Development, LLC, Johnson & Johnson, Kyowa Hakko Kirin Co., Ltd., LegoChem Biosciences, Inc, LEO Pharma A/S, Lixte Biotechnology Holdings, Inc., Madam Therapeutics B.V., Marinomed Biotechnologie GmbH, Maruho Co., Ltd., MedImmune, LLC, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Nabriva Therapeutics AG, NeoPharm Co., Ltd., Novan, Inc., Novartis AG, Nuvo Research Inc., Otsuka Holdings Co., Ltd., Oxagen Limited, Pergamum AB, Pfizer Inc., Pharis Biotec GmbH, Pharmedartis GmbH, Phosphagenics Limited, ProCertus BioPharm Inc., Promius Pharma, LLC, Provectus Biopharmaceuticals, Inc., R-Tech Ueno, Ltd., Reata Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., RestorGenex Corporation, Stemnion, Inc, sterna biologicals Gmbh & Co KG, Sun Pharma Advanced Research Company Ltd., SWITCH Biotech LLC, Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Thesan Pharmaceuticals, Inc., Upsher-Smith Laboratories, Inc., Valeant Pharmaceuticals International, Inc., Vicore Pharma AB, Vida Therapeutics Inc., Vitae Pharmaceuticals, Inc., VivaCell Biotechnology Espana S.L., Welichem Biotech Inc., XBiotech USA, Inc., Xencor, Inc., Yungjin Pharm Ind. Co., Ltd. and Ziarco Pharma Ltd.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=365305 . (This is a premium report priced at US$2000 for a single user License.)

List of Tables
Number of Products under Development for Dermatitis, H1 2015 23
Number of Products under Development for Dermatitis - Comparative Analysis, H1 2015 24
Number of Products under Development by Companies, H1 2015 26
Number of Products under Development by Companies, H1 2015 (Contd..1) 27
Number of Products under Development by Companies, H1 2015 (Contd..2) 28
Number of Products under Development by Companies, H1 2015 (Contd..3) 29
Number of Products under Development by Companies, H1 2015 (Contd..4) 30
Number of Products under Development by Companies, H1 2015 (Contd..5) 31
Number of Products under Development by Companies, H1 2015 (Contd..6) 32
Number of Products under Investigation by Universities/Institutes, H1 2015 33
Comparative Analysis by Late Stage Development, H1 2015 34
Comparative Analysis by Clinical Stage Development, H1 2015 35
Comparative Analysis by Early Stage Development, H1 2015 36
Comparative Analysis by Unknown Stage Development, H1 2015 37
Products under Development by Companies, H1 2015 38
Products under Investigation by Universities/Institutes, H1 2015 47

List of Figures
Number of Products under Development for Dermatitis, H1 2015 23
Number of Products under Development for Dermatitis - Comparative Analysis, H1 2015 24
Number of Products under Development by Companies, H1 2015 25
Number of Products under Investigation by Universities/Institutes, H1 2015 33
Comparative Analysis by Late Stage Development, H1 2015 34
Comparative Analysis by Clinical Stage Development, H1 2015 35
Comparative Analysis by Early Stage Products, H1 2015 36
Assessment by Monotherapy Products, H1 2015 135
Number of Products by Top 10 Targets, H1 2015 136
Number of Products by Stage and Top 10 Targets, H1 2015 136
Number of Products by Top 10 Mechanism of Actions, H1 2015 140
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 140
Number of Products by Top 10 Routes of Administration, H1 2015 143
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 144
Number of Products by Top 10 Molecule Types, H1 2015 145
Number of Products by Stage and Top 10 Molecule Types, H1 2015 145

Explore more reports on Dermatology therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/dermatology-therapeutics .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Ritesh Tiwari, RnR Market Research, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.